A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs LY-3316531 (Primary) ; LY-3316531 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 05 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Jul 2019 Planned End Date changed from 2 Sep 2019 to 2 Aug 2019.
- 14 Jan 2019 Status changed from recruiting to active, no longer recruiting.